ZMIZ2 promotes the development of triple-receptor negative breast cancer

Xiaopan Zou1,2, Yan Liu1, Jun Di3, Wei Wei1, Nobumoto Watanabe4, Jiang Li5* and Xiaomeng Li1*

Abstract

Background: Triple-receptor negative breast cancer (TNBC) is an aggressive breast tumor subtype that generally has a poor prognosis. This study aimed to investigate the role and regulatory mechanisms of Zinc finger MIZ-type containing 2 (ZMIZ2) in relation to TNBC.

Methods: Based on data from The Cancer Genome Atlas (TCGA), the expression of ZMIZ2 in different subtypes and its correlation with androgen receptor (AR) were analyzed, and a regulatory mechanism network was constructed. The expression and prognostic value of ZMIZ2 in clinical TNBC tissue samples were also investigated. Furthermore, in vitro studies were conducted to investigate the effects of ZMIZ2 knockdown on the malignant behaviors of TNBC cells and target gene expression.

Results: Based on TCGA data, ZMIZ2 was found to be significantly upregulated in TNBC tissues and its expression was negatively correlated with AR expression. Key relationships, such as the ZMIZ2-CCL5, ZMIZ2/AR-MCM3, ZMIZ2/AR-E2F4, and the ZMIZ2/AR-DHX38 were identified, which were enriched in NOD-like receptor signaling pathway/toll-like receptor signaling pathway, DNA replication, cell cycle, and spliceosome, respectively. Moreover, ZMIZ2 was upregulated in clinical breast cancer tissues and its high expression was correlated with the poor prognosis of TNBC patients. Furthermore, ZMIZ2 expression was increased in breast cancer cells, and a knockdown of ZMIZ2 inhibited MDA-MB-231 cell proliferation, migration, and invasion, induced cell cycle arrest in the G1 phase, and promoted cell apoptosis. Furthermore, ZMIZ2 knockdown inhibited the mRNA and protein expression of CCL5, MCM3, E2F4, and DHX38.

Conclusion: Our findings reveal that ZMIZ2 is upregulated in TNBC tissues and is associated with its poor prognosis. ZMIZ2 may promote TNBC progression by promoting the expression of its target genes and affecting the corresponding pathways. Consequently, ZMIZ2 may serve as a promising target for future TNBC treatments.

Keywords: Triple-receptor negative breast cancer, ZMIZ2, Survival analysis, Regulatory network

Background

Breast cancer is the most common malignancy among women worldwide [1]. Among the different types of breast cancers, tumors that are immunohistochemically characterized as estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and human epidermal growth factor receptor 2 (HER2)-negative are classified as triple-receptor negative breast cancers (TNBCs), and they account for 15–20% of all breast cancers [2]. Compared with HER2-positive or hormone receptor-positive breast cancers, TNBCs have a more aggressive clinical course, earlier relapses, and a poorer overall prognosis, and thus represent a major challenge for patients and physicians [3, 4]. As the molecular mechanisms driving TNBC progression have not yet been fully elucidated,
targeted therapies have not yet significantly improved overall survival in TNBC patients [5]. Therefore, the development of novel targets for TNBC represents a critical and yet unmet clinical need.

Zinc finger MIZ-type containing 2 (ZMIZ2), also named ZIMP7, is a protein inhibitor of activated STAT (PIAS)-like protein and a transcriptional coactivator [6]. ZMIZ2 contains a C-terminal transactivation domain that can augment androgen receptor (AR)-mediated transcription [7, 8]. AR has been suggested to play a critical role in male sexual development, as well as in the growth and survival of normal and malignant prostate cells [6]. ZMIZ2 is highly expressed in the testis and promotes the growth of prostate cancer cells [6]. However, the role of ZMIZ2 in TNBC has not, to the best of our knowledge, been widely reported. AR seems to play an important role in the carcinogenesis of TNBC, as it is reportedly expressed in 10–50% of TNBC cases [9], and those with an AR-positive subtype are susceptible to AR blockades [9–11]. Given the regulatory relationship between ZMIZ2 and AR, as well as the role of AR in TNBC, we hypothesize that ZMIZ2 plays a key role in the carcinogenesis of TNBC, and thus, may serve as a novel biomarker for TNBC.

To confirm our speculations, we downloaded RNA-seq data and clinical information for breast cancer from The Cancer Genome Atlas (TCGA) database and analyzed it for ZMIZ2 expression and the correlation between ZMIZ2 and AR. The potential regulatory mechanisms of ZMIZ2 in TNBC were also explored using comprehensive bioinformatics analyses, such as differential expression analysis, protein–protein interaction analysis, pathway analysis and regulatory mechanism network construction. Moreover, the expression and prognostic value of ZMIZ2 in clinical TNBC tissue samples were investigated. Furthermore, in vitro studies were conducted to determine the expression, function, and mechanisms of ZMIZ2 in the TNBC cells. These findings will help to facilitate the development of novel therapeutic strategies for TNBC in the future.

**Methods**

**Bioinformatics analysis of ZMIZ2 expression in different breast cancer subtypes and its regulatory mechanisms in TNBC using TCGA data**

**Acquisition of RNA-seq data and clinical information**
The RNA-seq level 3 data and clinical information for breast cancer were downloaded from TCGA database (https://cancergenome.nih.gov/). A total of 845 samples were divided into luminal (580), HER2 (30), and TNBC (122) subtypes based on ER, PR, and HER2 status, and there were 113 normal samples. Additionally, according to their HER2 status, the samples were divided into HER2+ (110) and HER2− (622) groups.

**Analysis of ZMIZ2 expression in different breast cancer subtypes and its co-expression with AR**
To explore the role of ZMIZ2 in the different breast cancer subtypes, data about its expression was obtained from TCGA. Moreover, the correlation between ZMIZ2 and AR in the luminal, HER2, TNBC, HER2+, HER2−, and normal samples was separately calculated using the Pearson algorithm [12]. When p < 0.05, the relationship was considered to be a co-expression.

**Differential expression analysis**
Based on the RNA-seq level 3 data obtained from TCGA database, the differentially expressed (DE) mRNAs in TNBC when compared with the normal samples were calculated using the limma packet [13] of R language. The thresholds were set as |log fold change (FC)| > 0.75 and adj. p value < 0.05. Moreover, the differentially expressed (DE) mRNAs in TNBC when compared with the normal samples and with the HER2 samples, were identified using threshold values of |logFC| > 0.5 and adj. p value < 0.05.

**PPI and transcriptional regulatory analyses**
Based on the information of the STRING website [14], the PPIs for all the DE mRNA-corresponding proteins were predicted. We extracted the PPI for ZMIZ2 with the other DE mRNA-corresponding proteins, and constructed PPI networks.

Based on the transcription factor (TF)-target relations in the ENCODE database [15], a TF that could regulate ZMIZ2 was predicted from the DE mRNAs.

**Gene set enrichment analysis (GSEA) of ZMIZ2 regulatory pathways and construction of its regulatory mechanism network**
GSEA [16] was performed for TNBC, HER2, and normal samples. Based on the GSEA method, the positive and negative pathways of ZMIZ2 in 122 TNBC samples were identified using metrics to rank the genes using Pearson with ZMIZ2 as the key for the phenotypic labels. The thresholds were set to |NES| > 1.5 and p < 0.05. Using the same methods, the pathways involving ZMIZ2, in 113 normal and 30 HER2 samples, were analyzed. Additionally, Venn analyses of the positive and negative pathways between the TNBC and normal samples, as well as between the TNBC and HER2 samples, were performed. Based on results of the GSEA, we further constructed regulatory mechanism networks for ZMIZ2 based on the pathways common between the TNBC and normal samples, and TNBC and HER2 samples. Due to the large
initial network, we screened genes that had r correlation values > 0.3 with ZMIZ2 to use for the construction of the network. Considering the correlation between ZMIZ2 and AR, GSEA for AR in 122 of the TNBC samples was also performed to analyze its positive and negative pathways, and a Venn analysis of this data was conducted. Based on the GSEA results, the genes that were significantly correlated with ZMIZ2 and AR (|r| > 0.3) and enriched in four pathways related to proliferation regulation (including spliceosome, DNA replication, cell cycle, and homologous recombination) were selected to construct the regulatory mechanism network for ZMIZ2-AR.

Clinical analysis of ZMIZ2 expression in different breast cancer subtypes and the prognostic value of ZMIZ2 for TNBC when using clinical samples

**Tissue sample collection**
Breast cancer tissue samples (21 luminal, 21 HER2, and 24 TNBC) and 25 normal breast tissue samples were collected during 2018–2021. Each sample was divided into three parts for real-time quantitative reverse transcription-PCR (qRT-PCR), western blot, and immunohistochemical assays. The tissue samples for RNA and protein extraction were stored in liquid nitrogen within 2 weeks. The tissue resections for the immunohistochemical assay were fixed in formalin and embedded in paraffin. In addition to these samples, we retrospectively collected the paraffin specimens of patients with TNBC during 2008–2018 and assessed their ZMIZ2 expression. Based on the ZMIZ2 expression in all samples and follow-up information, survival analysis was conducted. This study was approved by the Ethics Committee of Jilin Province People’s Hospital. Informed consent was signed by all participants.

**qRT-PCR**
Total RNA was extracted using an RNA extraction solution (Servicebio, Wuhan, China). Reverse transcription was performed using a Servicebio® RT First Strand cDNA Synthesis kit (Servicebio), followed by PCR reactions with 2 × SYBR Green qPCR Master Mix (Servicebio). GAPDH was used as an internal control for mRNA. The $2^{-\Delta\DeltaCT}$ method was used for relative quantification. The primers (5′–3′) used for gene amplification are listed in Table 1.

**Western blot assay**
The samples were washed and lysed with RIPA buffer (Servicebio). Total proteins were extracted using a protein extraction kit (Nanjing KeyGen Biotech Co., Ltd., Nanjing, China). Before being transferred to the polyvinylidene fluoride (PVDF) membranes (Millipore, USA), total proteins (30–50 μg/per lane) were first separated on 10% sodium dodecyl sulfate-polyacrylamide gels. The membranes were blocked with 5% skim milk for 1 h, and then the primary antibodies [anti- ZMIZ2 (Abclonal, Wuhan, China), anti-CCL5 (Bioss, Beijing, China), anti-MCM3 (Abclonal), anti-E2F4 (Bioss), and anti-DHX38 (Bioss)] were added and incubated at 4 °C overnight. Following this, the membranes were conjugated with a secondary antibody (Bioss) for 30 min at 37 °C. Protein bands were visualized using an ECL detection kit (Servicebio). The intensities of the target bands were quantified by densitometry using AlphaEaseFC Software (Alpha Innotech, USA).

**Immunohistochemistry**
The paraffin sections (4-μm-thick) were soaked in 3% H₂O₂ for 10 min after dewaxing with xylene and alcohol baths. The sections were then soaked in antigen retrieval solution for 5 min. Then, PBS with 10% sheep serum (Gibco, Grand Island, NY, USA) was added to the section to block the non-specific sites. The primary antibody against ZMIZ2 (Abclonal) was added and then incubated at 4 °C overnight, followed by the incubation with the corresponding secondary antibody (Bioss). The images (200 × magnification) were photographed and the positive area density was analyzed using an Image-Pro Plus 6.0 System (Media Cybernetics Corporation, USA).

**Survival analysis**
To better understand the prognostic value of ZMIZ2 and MCM3 in TNBC, survival analysis was conducted. The TNBC samples were divided into high- and low-expression groups based on the median values of their gene expression. Kaplan–Meier survival curves were drawn using the R package based on the overall survival information (OS status and OS time) of the TNBC samples. Log-rank statistical tests were then performed, and a p < 0.05 indicated statistical significance.

| Table 1 | The primers (5′−3′) used in this study |
|---------|----------------------------------|
| **Primers** | **Forward** | **Reverse** |
| ZMIZ2 | CCTGGCTGTAAAGCAACCA | GCCAGTTGGTTCATCTGCG |
| MCM3 | CGAAGACCTAGAAATGGC | CGCAAGCCACATACGCA |
| CCL5 | CCTGCTGCTTGGCTCACA | ACACACTGGCCGTTCCTG |
| E2F4 | GGAAGGATCGGGCTTAAT | AGCTCCTCAGATCTCCTG |
| DHX38 | GCCCTGGATCAGCTAAG | GTGGCTGATGACGCAGAGAG |
| GAPDH | GGAGCGAGATCCCTC AAAT | GGCTGGTTCATCTTCATG |

Zou et al. Cancer Cell International (2022) 22:52
In vitro studies of ZMIZ2 expression in different breast cancer cell lines and the function and mechanisms of ZMIZ2 in TNBC cells

Cell culture
The breast epithelial cell line MCF-10A (American Type Culture Collection (ATCC), Manassas, VA) was maintained in Dulbecco’s Modified Eagle’s Medium (DMEM)/Ham’s F12 Medium (Gibco) supplemented with 20 ng/mL epidermal growth factor, 5% horse serum, and 500 ng/mL hydrocortisone (Life Technologies, USA). The luminal subtype cell line MCF-7, HER2 subtype cell line SKBR-3, and TNBC cell line MDA-MB-231 (ATCC) were cultured in DMEM supplemented with 10% fetal bovine serum (FBS), penicillin, and streptomycin (Life Technologies, USA). All cells were cultured in a 5% CO2 cell incubator at 37 °C. Notably, MDA-MB-231 cell line was authenticated by Short Tandem Repeat (STR) profiling before initiation of this study. ZMIZ2 mRNA and protein level expression levels were determined via qRT-PCR and western blot assays.

Cell transfection
Short hairpin RNAs (shRNAs) targeting ZMIZ2 were designed and their sequences are shown in Additional file 2: Table S1. They were cloned into the plenti-shRNA-GFP-puro vector (Shanghai GenePharma Co., Ltd.). The shRNA nontarget sequence was cloned into the lentiviral vector as a negative control. Positive colonies were selected by sequencing. The plenti-shRNA-GFP-puro recombinant vector and lentiviral packaging mix were subsequently transfected into HEK-293T cells using Effectene Transfection Reagent (QIAGEN, Germantown, MD). After 48 h of incubation, the supernatant containing recombinant lentivirus was harvested to assess transfection efficiency by detecting ZMIZ2 expression with qRT-PCR. Moreover, MDA-MB-231 cells were also transfected with plenti-shRNA-GFP-puro recombinant vector using the same Effectene Transfection Reagent to confirm the transfection efficiency.

CCK8 assay
MDA-MB-231 cells were seeded onto 96-well plates. Cell viability was evaluated using the CCK-8 kit (cat#E606335-0500, BBI Life Sciences, New York, USA) in accordance with the manufacturers’ instructions. Briefly, 10 μL of CCK8 solution was added to the cells, followed by incubation for 1 h at 37 °C. The absorbance at 450 nm was then measured using a microplate reader (Epoch2, BioTek, USA).

Detection of cell apoptosis
Cell apoptosis was detected using the Annexin V-FITC/PI Apoptosis Detection kit (cat#40302ES20; Yeasen, Pudong, Shanghai, China). Briefly, MDA-MB-231 cells in different transfection groups were digested with trypsin without EDTA and then collected by centrifugation. The cells were washed with pre-chilled PBS and then resuspended in 1 × binding buffer with a density of 1 × 10⁶ cells/mL. Subsequently, 100 μL cell suspension was stained with 5 μL Annexin V-FITC and 10 μL propidium iodide (PI) for 15 min at room temperature away from the light. Cell apoptosis was then detected using a flow cytometer (FC500, Beckman Coulter, Fullerton, CA, USA).

Transwell assays
Cell migration and invasion were assessed using Transwell assays. Briefly, MDA-MB-231 cells in different transfection groups were suspended in serum-free medium, and 100 μL of cell suspension was then seeded into the upper chamber of the Transwell insert (Corning, Costar, Cambridge, MA, USA). Notably, the insert was coated with Matrigel for the invasion assays. The lower chamber of the Transwell insert was filled with 600 μL of medium containing 20% FBS as a chemoattractant. After 24 h of incubation, the Transwell insert was washed with PBS, fixed with formaldehyde (BBI Life Sciences) for 30 min, and then stained with 0.1% crystal violet (BBI Life Sciences) for 30 min. The non-migrated or non-invaded cells remaining on the upper chamber were removed with cotton wool. Then, the cells that had migrated or invaded the membrane in three randomly selected fields (100 × magnification) were observed and counted using an inverted fluorescence microscope (CKX41, Olympus, Tokyo, Japan).

Cell cycle analysis
To estimate the dissemination of the MDA-MB-231 cells in the different phases of the cell cycle, MDA-MB-231 cells in different transfection groups were digested with trypsin and fixed with pre-cool 70% ethanol overnight at 4 °C. Cells were collected by centrifugation, suspended with PBS, and then incubated with 2.5 μL of RNase (10 mg/mL) for 30 min at 37 °C. The cells were then stained with 50 μL PI (10×, cat#E607306; Sangon Biotech Co., Ltd., Shanghai, China). Cell distribution was then determined within 2 h using a flow cytometer (FC500, Beckman Coulter).

Validation of mRNA and the protein expression of the key targets of ZMIZ2
Based on the GSEA results, the key prognostic genes in the regulatory mechanism networks of ZMIZ2 were selected for validation as they were correlated with ZMIZ2 and had prognostic value in TNBC. Four targets of ZMIZ2 were selected, including the C–C Motif
chemokine ligand 5 (CCL5), minichromosome maintenance complex component 3 (MCM3), E2F transcription factor 4 (E2F4), and DEAH-box helicase 38 (DHX38). The mRNA and protein expression of these targets was quantified via qRT-PCR and western blot assays.

**Statistical analysis**
GraphPad Prism v6.0 (GraphPad V6.0 Software Inc., San Diego, CA, USA) was used for data analysis. The data are shown as mean ± standard deviation (SD), followed by normal distribution tests. If the measurement data conformed to a normal distribution, a Student’s t-test was used for comparison to assess significant differences between two groups. If not, significant differences were analyzed using a Mann–Whitney U test. The Kaplan–Meier survival analysis was conducted, followed by a Log-rank statistical test. P < 0.05 was considered statistically significant.

**Results**
Bioinformatics analysis revealed the increased expression of ZMIZ2 expression in breast cancers and its regulatory mechanisms in TNBC using TCGA data

**Expression of ZMIZ2 between different breast cancer subtypes and its correlation with AR**
Based on TCGA data, the differences in ZMIZ2 expression between the different subtypes were analyzed. The expression of ZMIZ2 was significantly up-regulated in TNBC samples when compared to normal samples (p = 2.44E−32) or HER2 samples (p = 1.54E−07; Table 2). Moreover, the correlation between ZMIZ2 and AR in different subtypes of breast cancers was calculated (Table 3). We found negative correlations between ZMIZ2 and AR in the cancer tissue samples (r < 0), while the correlation was positive in the normal tissue samples (r > 0). Additionally, the correlations were significant in the TNBC, luminal, HER2−, and all breast cancers samples, but there was no significant correlation in HER2 and HER2+ samples.

**Identification of DE mRNAs**
Based on the thresholds of |logFC|> 0.75 and adj.p value < 0.05, 3833 mRNAs differentially expressed between the TNBC and normal samples were selected, 1729 and 2104 of which were upregulated and downregulated, respectively. The hierarchical clustering heatmap is shown in Fig. 1A. The TNBC and normal samples were well distinguished by these DE mRNAs. Moreover, a total of 2012 DE mRNAs (1240 upregulated and 772 downregulated) between the TNBC and HER2 samples were identified with the thresholds of |logFC|> 0.5 and adj.p value < 0.05 (Fig. 1B).

**PPI networks and transcriptional regulatory relationships between ZMIZ2 and DE mRNAs**
Based on the information from the STRING database, the PPI pairs of DE mRNAs between the TNBC and HER2 samples were predicted, and the PPI pairs interacting directly with ZMIZ2 were screened, and the DE mRNAs that could interact directly with them were further identified to construct the PPI network (Fig. 2B). Notably, an interaction between ZMIZ2 and AR was observed in the two PPI networks mentioned above (Fig. 2A, B).

---

**Table 2** The difference of ZMIZ2 expression between different subtypes

| Group          | logFC   | P value |
|----------------|---------|---------|
| Cancer-Normal  | 0.436174019 | 9.88E−17 |
| TNBC-Normal    | 0.786992  | 2.44E−32 |
| HER2-Normal    | 0.250674  | 0.00946  |
| Lum-Normal     | 0.371459  | 3.23E−13 |
| Lum-TNBC       | 0.415533  | 5.76E−17 |
| Lum-HER2       | 0.110785  | 0.225652 |
| TNBC-HER2      | 0.526317  | 1.54E−07 |
| HER2 (POS-NEG) | −0.19074 | 0.000279 |

**Table 3** The correlations between ZMIZ2 and AR in different subtypes of breast cancers as well as all breast cancer and normal tissues

| Breast cancer subtypes | Gene 1 | Gene 2 | r    | P value      |
|------------------------|--------|--------|------|--------------|
| All breast cancers     | ZMIZ2  | AR     | −0.32766 | < 2.2e−16 |
| TNBC                   | ZMIZ2  | AR     | −0.37441 | 2.15E−05   |
| LUM                    | ZMIZ2  | AR     | −0.13049 | 0.001636   |
| HER2                   | ZMIZ2  | AR     | −0.06272 | 0.742       |
| HER2+                  | ZMIZ2  | AR     | −0.04444 | 0.6387      |
| Normal                 | ZMIZ1  | AR     | −0.3448  | < 2.2e−16  |
| Normal                 |        |        | 0.4078161| 7.344e−06  |
The transcriptional regulatory relationship between ZMIZ2 and the DE mRNAs in TNBC vs. the normal group was predicted, and 10 DE mRNAs (WRNIP1, RAD21, BCL11A, E2F1, ZEB1, TCF4, EGR1, EBF1, JUND, and FOXA1) were found to be TFs of ZMIZ2 (Fig. 2C). Furthermore, the transcriptional regulatory relationships between ZMIZ2 and DE mRNAs belonging to the TNBC and HER2 groups were predicted, and 5 DE mRNAs (CEBPB, BCL11A, MUC, SRF, and FOXA1) were found to be TFs of ZMIZ2 (Fig. 2D).

The ZMIZ2 regulatory pathway in TNBC, HER2, and normal samples

Using ZMIZ2 as phenotype labels, the positive and negative pathways (top 20 based on NES) regulated by ZMIZ2 in the TNBC, normal, and HER2 samples are shown in Additional file 2: Tables S2–S4. Venn analysis showed the key pathways regulated by ZMIZ2, and there were obvious differences between the TNBC and normal samples (Additional file 1: Fig. S1A). Among the top 20 (based on NES) pathways in the TNBC-positive group, were 8 immune system-related and 6 immune disease-related pathways (Table 4). We focused on the immune-related pathways in the following analyses. Based on the analysis results of GSEA, we further constructed the regulatory mechanism network of ZMIZ2. Due to the large initial network, we selected the genes that had r correlations > 0.3 with ZMIZ2 to construct the network. Finally, a network with 60 nodes (4 pathway nodes and 56 gene nodes) and 118 edges was constructed (Fig. 3B). Key relationships, such as ZMIZ2-MCM3, ZMIZ2-E2F4, and ZMIZ2-DHX38 were obtained, which were enriched in DNA replication, cell cycle, and spliceosome, respectively, suggesting that these genes and corresponding proliferation-related pathways might contribute to TNBC development.
The AR regulatory pathway in TNBC samples

In the abovementioned analysis, there were negative correlations between ZMIZ2 and AR in the TNBC samples, and consequently, we conducted GSEA of the AR regulatory pathway. The results of the GSEA revealed the positive and negative pathways (top 20 based on NES) regulated by AR in the TNBC samples (Additional file 2: Table S5). Venn analysis showed that 44 ZMIZ2-positive pathways were the same as the AR-negative pathways, and 13 ZMIZ2-negative pathways were the same as the AR-positive pathways (Additional file 1: Fig. S1C). These data confirmed the negative correlations between ZMIZ2 and AR. Based on the GSEA results, we selected four proliferation-related pathways regulated by ZMIZ2-AR in the TNBC samples, including the spliceosome, DNA replication, cell cycle, and homologous recombination. When the r > 0.3, 185 and 173 genes belonging to four pathways were found to be associated with ZMIZ2 and AR, respectively. In combination with the DE mRNAs between the TNBC and normal samples and prognostic genes, the regulatory mechanism network for ZMIZ2-AR was constructed, including 4 pathways and 41 gene nodes (Fig. 4). Notably, key ZMIZ2-regulatory genes, such as MCM3, E2F4, and DHX38 were also regulated by AR. Key relationships, such as AR-MCM3, AR-E2F4, and AR-DHX38 were identified.

ZMIZ2 expression was up-regulated in different breast cancer subtypes and was associated with poor prognosis in clinical TNBC patients

Expression of ZMIZ2 in different breast cancer subtypes

The expression level of ZMIZ2 in the different breast cancer subtype tissue samples was quantified. qRT-PCR revealed that ZMIZ2 mRNA was significantly
upregulated in cancer tissues in comparison with the controls (P < 0.05; Fig. 5A). Specifically, ZMIZ2 had the highest mRNA expression in the TNBC tissues, which was in accordance with the results of the aforementioned data analysis. Moreover, consistent results were obtained from western blot and immunohistochemistry: protein expression levels of ZMIZ2 were significantly increased in cancer tissues, especially the TNBC tissues, when compared with the control (P < 0.05, Fig. 5B, C).

**Table 4** Among the top 20 (based on NES) pathways in TNBC-positive group, there were 8 immune system-related and 6 immune disease-related pathway

| Name                                     | NES          | Pathway type                                      |
|-------------------------------------------|--------------|---------------------------------------------------|
| KEGG_ALLOGRAFT_REJECTION                  | 2.5076501    | Immune disease                                   |
| KEGG_LEISHMANIA_INFECTION                 | 2.4929893    | Infectious disease: parasitic                     |
| KEGG_NODLIKE_RECEPTOR_SIGNALING_PATHWAY   | 2.416907     | Immune system                                    |
| KEGG_GRAFT_VERSUS_HOST_DISEASE            | 2.3912017    | Immune system                                    |
| KEGG_ANTIGEN_PROCESSING_AND_PRESENTATION | 2.3886569    | Immune system                                    |
| KEGG_PRIMARY_IMMUNODEFICIENCY             | 2.3744943    | Immune disease                                   |
| KEGG_NATURAL_KILLER_CELL_MEDIATED_CYTOTOXICITY | 2.350802 | Immune system                                    |
| KEGG_TYPE_I_DIABETES_MELLITUS             | 2.3472748    | Endocrine and metabolic disease                   |
| KEGG_CHEMOKINE_SIGNALING_PATHWAY          | 2.3357153    | Immune system                                    |
| KEGG_SYSTEMIC_LUPUSERYTHEMATOSUS          | 2.3204288    | Immune disease                                   |
| KEGG_B_CELL_RECEPTOR_SIGNALING_PATHWAY    | 2.2692728    | Immune system                                    |
| KEGG_INTESTINAL_IMMUNE_NETWORK_FOR_IGA_PRODUCTION | 2.247273 | Immune system                                    |
| KEGG_AUTOIMMUNE_THYROID_DISEASE           | 2.2273605    | Immune disease                                   |
| KEGG_TOLLLIKE_RECEPTOR_SIGNALING_PATHWAY  | 2.2212996    | Immune system                                    |
| KEGG_FC_GAMMA_R_MEDIATED_PHAGOCYTOSIS     | 2.1360247    | Immune system                                    |
| KEGG_ASTHMA                                | 2.0703006    | Immune disease                                   |
| KEGG_PROTEASOME                           | 2.0634766    | Folding, sorting and degradation                 |
| KEGG_VIRAL MYOCARDITIS                    | 1.9749774    | Cardiovascular disease                           |
| KEGG_BASAL_TRANSCRIPTION_FACTORS          | 1.934293     | Transcription                                    |

*Fig. 3* Gene-pathway regulatory mechanism networks for ZMIZ2 based on the gene set enrichment analysis (GSEA) results. A Regulatory mechanism networks of ZMIZ2 based on the pathways between the TNBC and normal samples. B Regulatory mechanism networks of the ZMIZ2 based on the pathways between the TNBC and HER2 samples. Red circle nodes represent upregulated genes, and blue circle nodes represent non-differentially expressed genes. Square nodes represent pathways.
low-expression groups. High expression levels of ZMIZ2 or MCM3 were significantly correlated with a poor prognosis for clinical patients with TNBC ($P = 0.013$ and $P = 0.045$, respectively, Fig. 5D, E).

**In vitro validation of the ZMIZ2 expression in breast cancer cell lines and the oncogenic role of ZMIZ2 in TNBC cells**

The expression levels of ZMIZ2 were assessed in the three breast cancer cell lines and the breast epithelial cells. As expected, the mRNA and protein expression levels of ZMIZ2 were upregulated in MDA-MB-231, MCF-7, and SKBR-3 cells when compared with the MCF-10A cells ($P < 0.05$, Fig. 6A, B). Specifically, the expression of ZMIZ2 was highest in the MDA-MB-231 cells.

**ZMIZ2 was successfully knocked down after transfection**

To investigate the role of ZMIZ2 in TNBC, ZMIZ2 was knocked down by transfection with shRNAs targeting ZMIZ2. As revealed in Fig. 6C, ZMIZ2 was successfully knocked down in 293T cells by transfection with SH1 or SH3 ($P < 0.05$). The MDA-MB-231 cells were then further transfected with SH1 or SH3 to confirm their inhibitory effects on ZMIZ2 expression. Compared with the control, SH1 or SH3 transfection resulted in a significant decrease in ZMIZ2 mRNA expression.

---

**Fig. 4** Regulatory mechanism networks for ZMIZ2-AR based on the pathways between the TNBC and normal samples. Red circle nodes represent upregulated genes, green circle nodes represent downregulated genes, and blue circle nodes represent non-differentially expressed genes. Square nodes represent pathways.

**Fig. 5** ZMIZ2 expression was upregulated in different breast cancer subtypes and associated with poor a prognosis in clinical TNBC patients. A qRT-PCR revealed the upregulation of ZMIZ2 mRNA expression in different breast cancer subtypes. B Western blot assay showed the upregulation of ZMIZ2 protein expression in different breast cancer subtypes. C An immunohistochemical assay showed the upregulation of ZMIZ2 protein expression in different breast cancer subtypes. Magnification: $200 \times$, bar scale: $100 \mu m$. D Kaplan–Meier survival curves for high- and low-expression of ZMIZ2 in clinical patients with TNBC. E: Kaplan–Meier survival curves for high- and low-expression of MCM3 in clinical patients with TNBC. *$P < 0.05$ and **$P < 0.01$ when compared with the normal controls.
Fig. 5 (See legend on previous page.)
Similarly, the results of western blot assay showed that ZMIZ2 protein expression was significantly decreased in the MDA-MB-231 cells transfected with ZMIZ2-SH3 (P < 0.05, Fig. 7B). These data confirmed that ZMIZ2 was successfully knocked down in the MDA-MB-231 cells after transfection. SH3 was then selected in subsequent experiments as it had a stronger inhibitory effect than SH1 in the MDA-MB-231 cells.

Knockdown of ZMIZ2 inhibited MDA-MB-231 cell proliferation, migration, and invasion, induced cell cycle arrest in G1 phase, and promoted cell apoptosis

To explore the function of ZMIZ2 in TNBC, the in vitro effects of the ZMIZ2 knockdown on MDA-MB-231 cell proliferation, migration, invasion, cell cycle, and apoptosis were investigated. The results of the CCK8 showed that the cell viability of the MDA-MB-231 cells was significantly suppressed after the knockdown of ZMIZ2 by transfection with SH3 (P < 0.01, Fig. 6E). The results of the Transwell assays confirmed that the knockdown of ZMIZ2 significantly inhibited the migration and invasion of MDA-MB-231 cells. Magnification: 100 ×; bar scale: 50 μm. H Cell cycle analysis revealed that the knockdown of ZMIZ2 induced G1 phase arrest. I Flow cytometry showed that the knockdown of ZMIZ2 promoted MDA-MB-231 cell apoptosis. *P < 0.05, **P < 0.01, and ***P < 0.001 when compared with the corresponding controls.

Validation of the expression of key targets of ZMIZ2 in the MDA-MB-231 cells

Based on the above bioinformatics analysis, key targets of ZMIZ2, such as CCL5, MCM3, E2F4, and DHX38 were selected for validation, as they were found to be significantly correlated with ZMIZ2 and had prognostic value in patients with TNBC. CCL5, MCM3, E2F4, and DHX38 mRNA expression was significantly decreased in the ZMIZ2-SH3 group when compared
to the control group (P < 0.05; Fig. 7A). Moreover, we quantified the protein expression levels of CCL5, MCM3, E2F4, and DHX38 via western blot assay. The results showed that, as expected, knockdown of ZMIZ2 resulted in significant decreases in the protein expression levels of CCL5, MCM3, E2F4, and DHX38 (P < 0.05, Fig. 7B). These data suggest that ZMIZ2 might contribute to TNBC development via interactions with these targets.

**Discussion**

TNBC is an aggressive breast tumor subtype with a poor prognosis, that requires improved and more targeted treatment options [17, 18]. This is in-part because the molecular mechanisms underlying TNBC have not yet been completely elucidated. In the present study, the roles, and possible mechanisms of ZMIZ2 in TNBC were explored. Based on TCGA data, we found that ZMIZ2 was significantly upregulated in TNBC tissues...
and had significant negative correlations with AR in TNBC tissues. Following a series of bioinformatics analyses, crucial relationships, such as ZMIZ2-CCL5, ZMIZ2-AR-MCM3, ZMIZ2-AR-E2F4, and ZMIZ2-AR-DHX38 were identified. Moreover, based on the clinical samples, ZMIZ2 was confirmed to be upregulated in clinical breast cancer tissues and its high expression levels were correlated with a poor prognosis for TNBC patients. Furthermore, in vitro experiments revealed that ZMIZ2 expression was increased in breast cancer cells, and the knockdown of ZMIZ2 inhibited MDA-MB-231 cell proliferation, migration, and invasion, induced cell cycle arrest in G1 phase, and promoted cell apoptosis. Furthermore, the mRNA and protein expression of the key targets of ZMIZ2, including CCL5, MCM3, E2F4, and DHX38 were inhibited after its knockdown. To the best of our best knowledge, this is the first study to demonstrate the role and potential regulatory mechanisms of ZMIZ2 in TNBC.

ZMIZ2 is a PIAS-like protein that can modulate the activity of different TFs, such as p53, SMAD family members (Smads), and nuclear hormone receptors [19, 20]. p53 is a well-known tumor suppressor, the inactivation of which is implicated in the aggressiveness of TNBC as it promotes metastasis, and resistance to therapy [21]. Smads are key downstream targets of the activin-signaling pathway [22]. Activin and activin-signaling receptors have also been shown to play a pivotal role in maintaining control over cellular proliferation in breast cancer [23]. In addition, ZMIZ2 is identified as an AR-interacting protein that can augment AR-mediated transcription [24]. AR is reported to be expressed in 10–50% of TNBCs and may play a pivotal role in their carcinogenesis [9]. These results all indirectly indicate that ZMIZ2 has a critical role in TNBC. By combining data from TCGA, clinical tissue studies, and in vitro studies, this study has elucidated that ZMIZ2 is upregulated in TNBC tissues and cells. Moreover, for the first time, we have shown that knockdowns of ZMIZ2 inhibit MDA-MB-231 cell proliferation, migration, and invasion, induced cell cycle arrest in the G1 phase, and promoted cell apoptosis. These findings further reveal the oncogenic role of ZMIZ2 in TNBC and suggest its potential as a therapeutic target in the future. Furthermore, ZMIZ2 may regulate other genes through its PIAS activity or through transcriptional regulation. Although ZMIZ2 has been shown to augment AR-mediated transcription via its PIAS activity [24], the effects of ZMIZ2 on AR expression via transcriptional regulation were previously largely unknown. Our study revealed that ZMIZ2 expression was negatively correlated with AR expression in TNBC, using TCGA data. We thus speculated that AR expression and activity may be regulated by different mechanisms. Further experiments are required to confirm their relationships.

The interplay between individual cells in the tumor, the microenvironment, as well as the immune system contributes to cancer progression [25]. Some recent studies have revealed that when compared with other types of breast cancers, there are increased tumor-infiltrating lymphocytes in TNBC. Additionally, there are correlations between specific immune subsets and prognosis, but this requires more clinical investigation of their potential as immunotherapeutic agents in TNBC [26, 27]. In accordance with the reports above, our study showed that among the top 20 positive pathways regulated by ZMIZ2 in TNBC when compared to normal samples, 14 were immune system- and immune disease-related, which further indicated the critical role of the immune system in modulating the progression of TNBC. Based on these immune-related pathways and ZMIZ2-correlated genes, a ZMIZ2-regulated immune pathway-gene network was constructed. In this network, CCL5 was a prognostic gene, which was involved in the NOD-like receptor signaling pathway and toll-like receptor signaling pathway. It has been reported that the NOD-like receptor signaling pathway is active in many diseases, including inflammatory and autoimmune disorders, and cancer [28]. Yimam et al. [29] reported that the stimulation of NOD-like receptors could activate mitogen-activated protein kinases and nuclear factor-κB to drive the transcription of genes that were involved in innate and adaptive immune responses. A recent study has demonstrated that the upregulation of ubiquitin specific protease 21 promotes the tumorigenic capability of TNBC cells via the NOD-like receptor signaling pathway [30]. Toll-like receptors are primarily expressed in human immune and epithelial cells, and they function to trigger inflammatory responses by promoting the synthesis and release of inflammatory cytokines [31, 32]. Importantly, several toll-like receptors have been correlated with TNBC [33, 34]. Therefore, we speculated that ZMIZ2 may promote the progression of TNBC by regulating CCL5 to activate the NOD-like receptor signaling pathway and toll-like receptor signaling pathway. Notably, among the positive pathways regulated by ZMIZ2, the most common pathways in both the TNBC and HER2 samples were immune-related, such as the NOD-like receptor signaling pathway. These data further suggest that both TNBC and HER2 subtypes may be closely associated with immunity.

Furthermore, among the specific positive pathways regulated by ZMIZ2 in TNBC, when compared with the HER2 samples, most were associated with proliferation, such as the spliceosome, DNA replication, and cell cycle
pathways. Moreover, these proliferation-related pathways were regulated by AR in TNBC samples. It is well-known that the proliferation of neoplastic cells is an important feature during tumor growth. Thus, we speculated that ZMIZ2 and AR may be involved in TNBC development by regulating the key pathways related to proliferation. In addition, MCM proteins are a group of helicases, which play a fundamental role in the replication of eukaryotic DNA [35]. The MCM3 protein is present in quiescent or differentiated cells at lower intracellular levels. Importantly, MCM3 is overexpressed in some human cancers, including breast cancers [36, 37]. The phosphorylation of MCM3 can negatively regulate DNA replication and checkpoint activation [38]. Moreover, overexpression of lncRNA CARMN promotes the prognosis and chemosensitivity of TNBC through the inhibition of DNA replication [39], suggesting a potential role of DNA replication in TNBC. In this study, ZMIZ2, AR, and MCM3 were enriched in DNA replication, and ZMIZ2/AR-MCM3 relationships were obtained. Therefore, we speculated that ZMIZ2-MCM3 and AR-MCM3 may be key relationships pertaining to DNA replication. E2F4 is a key regulator of cell cycle that is widely associated with tumorigenesis and cancer severity [40, 41]. Cell cycle genes have been revealed to be evolutionarily conserved targets of E2F4 [42], and E2F4 expression is required for cell cycle progression of colorectal cancer cells [43]. Herein, ZMIZ2/AR-E2F4 relationships were obtained, and these three genes were enriched in cell cycle, suggesting that ZMIZ2-E2F4 and AR-E2F4 were crucial relationships related to cell cycle. DHX38 is a slicing factor that is involved in the etiology of early-onset retinitis pigmentosa [44, 45]. Fraile et al. has demonstrated that DHX38 encodes an USP39-interacting splicing factor, whose depletion reduces the viability of KRAS-active cells, and thus, affects KRAS-driven cancers [46]. The crucial relationships ZMIZ2/AR-DHX38 were obtained, and these three genes were enriched in spliceosome. Therefore, we speculate that ZMIZ2-DHX38 and AR-DHX38 may affect the spliceosome to contribute to the proliferation of TNBC cells. Given the negative correlation between ZMIZ2 expression and AR expression, it is not clear whether they have opposite effects when they modulate the same pathway. Further in-depth investigation of the underlying mechanism is warranted to elucidate their roles in these pathways.

There are some limitations to our study. First, the negative correlation between ZMIZ2 expression and AR expression was not validated in the clinical patient samples. Second, key relationships such as ZMIZ2/AR-MCM3, ZMIZ2/AR-E2F4, and ZMIZ2/AR-DHX38 were not confirmed via experimental validation. Finally, whether ZMIZ2 was modulated at different stages of breast cancer was not determined due to lack of public or clinical data. Further studies with large samples and more experiments are required to verify our observations.

**Conclusions**

In conclusion, this study has demonstrated for the first time that ZMIZ2 is upregulated in TNBC, and that this may be associated with a poor prognosis for TNBC patients. Knockdowns of ZMIZ2 may inhibit TNBC cell proliferation, migration, and invasion, induce cell cycle arrest in the G1 phase, and promote cell apoptosis. Further analysis suggests that ZMIZ2 may promote the progression of TNBC by promoting CCL5, which affects several immune-related pathways, such as the NOD-like receptor signaling pathway and the toll-like receptor signaling pathway. Additionally, ZMIZ2 is negatively correlated with AR, and ZMIZ2 and AR may promote the proliferation of TNBC cells by regulating MCM3-DNA replication, the E2F4-cell cycle, and the DHX38-spliceosome. ZMIZ2 may thus serve as a promising biomarker or target for TNBC in the future.

**Abbreviations**

TNBC: Triple-receptor negative breast cancer; TCGA: The Cancer Genome Atlas; ER: Estrogen receptor; PR: Progesterone receptor; HER2: Human epidermal growth factor receptor 2; ZMIZ2: Zinc finger MIZ-type containing 2; PIAS: Protein inhibitor of activated STAT; AR: Androgen receptor; FC: Fold change; TF: Transcription factor; GSEA: Gene set enrichment analysis; qRT-PCR: Real-time quantitative reverse transcription-PCR; PVDF: Polyvinylidene fluoride; FBS: Fetal bovine serum; shRNA: Short hairpin RNA; SD: Standard deviation.

**Supplementary Information**

The online version contains supplementary material available at https://doi.org/10.1186/s12935-021-02399-x.

**Additional file 1: Fig. S1.** Venn analysis showed the key pathways regulated by ZMIZ2 between the TNBC and normal samples (A), and key pathways regulated by ZMIZ2 between the TNBC and HER2 samples (B), as well as the key pathways regulated by ZMIZ2 and AR (C). The sequences of the short hairpin RNAs (shRNAs) targeting ZMIZ2.

**Additional file 2: Table S1.** The sequences of the short hairpin RNAs (shRNAs) targeting ZMIZ2.

**Table S2.** The positive and negative pathways (top 20 based on NES) regulated by ZMIZ2 in the TNBC samples. Table S3. The positive and negative pathways (top 20 based on NES) regulated by ZMIZ2 in the HER2 samples.

**Table S3.** The positive and negative pathways (top 20 based on NES) regulated by ZMIZ2 in the normal samples.

**Table S4.** The positive and negative pathways (top 20 based on NES) regulated by ZMIZ2 in the normal samples.

**Acknowledgements**

None.

**Authors’ contributions**

Conception and design of the research: XZ, XL; acquisition of data: YL, WW; analysis and interpretation of data: JD, JL; statistical analysis: NM; obtaining funding: XL, JL; drafting the manuscript: XZ; revision of manuscript for important intellectual content: XL, JL. All authors read and approved the final manuscript.
Funding
This work was supported by the National Natural Science Foundation of China (Grant Number 31870758), the Ministry of Science and Technology (Grant Number 2016YFE0138500), and the Jilin Provincial Science & Technology Department (Grant Number 20200201025JC).

Availability of data and materials
All data generated or analyzed during this study are included in this published article.

Declarations

Ethics approval and consent to participate
This study was approved by the Ethics Committee of Jilin Province People’s Hospital.

Consent for publication
Informed consent was signed by all participants.

Competing interests
The authors declare that they have no competing interests.

Author details
1. The Key Laboratory of Molecular Epigenetics, Institute of Genetics and Cytology, Northeast Normal University, No.5268 Renmin Street, Nanguan District, Changchun 130024, Jilin, China. 2. Breast and Thyroid Surgery, Jilin Province People’s Hospital, Changchun 130021, Jilin, China. 3. Pathological Diagnostic Center, Jilin Province People’s Hospital, Changchun 130021, Jilin, China. 4. Bio-Active Compounds Discovery Research Unit, RIKEN Center for Sustainable Resource Science, Wako, Saitama, Japan. 5. Affiliated Stomatology Hospital of Guangzhou Medical University, Guangzhou 510180, Guangdong, China.

Received: 15 June 2021 Accepted: 4 December 2021
Published online: 31 January 2022

References

1. Siegel RL, Miller KD, Goding Sauer A, Fedewa SA, Butterfly LF, Anderson JC, Cernek A, Smith RA, Jermal A. Colorectal cancer statistics, 2020. CA Cancer J Clin. 2020;70:145–64.
2. Brown M, Tsidiohova B, Bauer KR, Parise CA, Caggiano V. The role of human epidermal growth factor receptor 2 in the survival of women with estrogen and progesterone receptor-negative, invasive breast cancer: The California Cancer Registry, 1999–2004. Cancer. 2008;112(4):737–47.
3. Denl R, Trudea M, Pritchard KL, Hanno WM, Kahan HK, Sawka CA, Lickley LA, Rawlinson E, Sun P, Narod SA. Triple-negative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res. 2007;13(15):4429–34.
4. Oishi M, Newman S, Murthy V, Tokumaru Y, Yan L, Matsuyama R, Endo I, Takabe K. TIPPC as a prognostic and predictive biomarker of neo-adjuvant chemotherapy for triple negative breast cancer. Cancers. 2020;12(10):2758.
5. Garrido-Castro AC, Lin NU, Poljak K. Insights into molecular classifications of triple-negative breast cancer: improving patient selection for treatment. Cancer Discov. 2019;9(2):176–98.
6. Lee SH, Zhu C, Peng Y, Johnsson DT, Lehmann L, Sun Z. Identification of a novel role of ZM22a protein in regulating the activity of the Wnt/β-catenin signaling pathway. J Biol Chem. 2013;288(50):35913–24.
7. Belakoff J, Sun Z. Zimp7 and Zimp10, two novel PIAS-like proteins, function as androgen receptor coregulators. Nucleic Acid Res. 2006;44(1):4017.
8. Sharma M, Li X, Wang Y, Zarnegar M, Huang CY, Palivmo JJ, Lim B, Sun Z. HZimp10 is an androgen receptor co-activator and forms a complex with SUMO-1 at replication foci. EMBO J. 2003;22(22):6101–14.
9. Gerratana L, Basile D, Caggiano V, Giordano D, Minichillo S, Cadeddu A, Monturano F, Di Stefano I, Del Mastro L. Androgen receptor in triple negative breast cancer: a potential target for the targetless subtype. Cancer Treat Rev. 2018;68:102–10.
10. Cochrane DR, Bernales S, Jacobsen BM, Cittelly DM, Howe EN, D’Amato NC, Spoelstra NS, Edgerton SM, Jean A, Guerrero J. Role of the androgen receptor in breast cancer and preclinical analysis of enzalutamide. Breast Cancer Res. 2014;16(1):R7.
11. Safapour D, Pakravesh S, Ravazzoli FA. Androgen receptor (AR) expression in 400 breast carcinomas: is routine AR assessment justified? Am J Cancer Res. 2014;4(4):333.
12. Feng W, Zhu Q, Zhuang J, Yu S. An expert recommendation algorithm based on Pearson correlation coefficient and FP-growth. Clust Comput. 2019;22(3):7401–12.
13. Ritchie ME, Phipson B, Wu D, Hu Y, Law CW, Shi W, Smyth GY. Limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Res. 2015;43(2):e47.
14. Mering CV, Huyten M, Jaeggi D, Schmidt M, Bork P, Snel B. STRING: a database of predicted functional associations between proteins. Nucleic Acids Res. 2003;31(1):258–61.
15. Qu H, Fang X. A brief review on the human encyclopedia of DNA elements (ENCODE) project. Genomics Proteomics Bioinform. 2013;11(3):135–41.
16. Subramanian A, Kuehn H, Gould J, Tamayo P, Mesirov JP. GSEA-P: a desktop application for Gene Set Enrichment Analysis. Bioinformatics. 2007;23(23):3251–3.
17. Vagia J, Mahalingam D, Cristofanilli M. The landscape of targeted therapies in TNBC. Cancers. 2020;12(4):916.
18. Nedeljkovic M, Damjanovic M. Mechanisms of chemotherapy resistance in triple-negative breast cancer-how we can rise to the challenge. Cells. 2019;8(9):957.
19. Schmidt D, Muller S, PIAS/SUMO: new partners in transcriptional regulation. Cell Mol Life Sci. 2003;60(12):2561–74.
20. Megidish T, Xu JH, Xu CW. Activation of p53 by protein inhibitor of activated Stat1 (PIAS1). J Biol Chem. 2002;277(10):6255–9.
21. Di Gennaro A, Damiano V, Brioschi G, Arminelli M, Perin T, Zucchetti A, Guardascione M, Spanik HP, Dogliotti C, Snaar-Jagalska BE. A p33/miR-30a/2E82 axis controls triple negative breast cancer aggressiveness. Cell Death Differ. 2018;25(12):2165–80.
22. Shi Y, Massagué J. Mechanisms of TGF-β signaling from cell membrane to the nucleus. Cell. 2003;113(6):685–700.
23. Seachrist DD, Keni RA. The activin social network: activin, inhibin, and follistatin in breast development and cancer. Endocrinology. 2019;160(5):1097–110.
24. Peng Y, Lee J, Zhu C, Sun Z. A novel role for protein inhibitor of activated STAT1 (PIAS1) proteins in modulating the activity of Zimp7, a novel PIAS-like protein, in androgen receptor-mediated transcription. J Biol Chem. 2010;285(15):11465–75.
25. Chen DS, Mellowman I. Elements of cancer immunity and the cancer–immune set point. Nature. 2017;541(7637):321–30.
26. Diis ML, Stanton SE. Triple-negative breast cancer: immune modulation as the new treatment paradigm. Am Soc Clin Oncol Educ Book. 2015;35(1):e25–30.
27. Eng SH, Ngio SF, Ribas A, Smyth MJ. Classifying cancers based on T-cell infiltration and PD-L1. Cancer Res. 2015;75(11):2139–45.
28. Saxena M, Yezeress G. NOD-like receptor: master regulators of inflammation and cancer. Front Immunol. 2014;5:327.
29. Yimam M, Lee Y-C, Moore B, Jiao P, Hong M, Nam J-H, Kim M-R, Hyun E-J, Chu M, Brownell L. Analogic and anti-inflammatory effects of UP1304, a botanical composite containing standardized extracts of Curcuma longa and Morus alba. J Integr Med. 2016;14(1):60–8.
30. Peng L, Hu Y, Chen D, Linghu R, Wang Y, Kou X, Yang J, Iao S. Ubiquitin specific protease 21 upregulation in breast cancer promotes cell tumorigenic capability and is associated with the NOD-like receptor signaling pathway. Oncol Lett. 2016;12(6):4531–7.
31. Johnston DG, Conn SC. Toll-like receptor signalling and the control of intestinal barrier function. In: Toll-like receptors. Springer; 2016. pp. 287–300.
32. Prac K, Demirel I, Bengtsson T, Khalaf H. The role of toll-like and protease-activated receptors in the expression of cytokines by gingival fibroblasts stimulated with the periodontal pathogen Porphyromonas gingivalis. Cytokine. 2015;76(2):424–32.
33. Nataraman S, Ranganathan M. Toll-like receptor (TLR) gene expression and immunostimulatory effect of CpG oligonucleotides in hormone receptor positive cell line T47D and triple negative breast cancer cell line MDA-MB-468. Immunopharmacol Immunotoxicol. 2020;42(5):408–15.
34. Zanker D, Spurling AJ, Brockwell NK, Owen KL, Zakhour JM, Robinson T, Duivenvoorden HM, Hertzog PJ, Mullins SR, Wilkinson RW. Intratumoral
administration of the Toll-like receptor 7/8 agonist 3M-052 enhances interferon-driven tumor immunogenicity and suppresses metastatic spread in preclinical triple-negative breast cancer. Clin Transl Immunol. 2020;9(9):e1177.

35. Valverde LDF, de Freitas RD, Pereira TDA, de Resende MF, Agra IM, dos Santos JN, dos Reis MG, Sales C, Gurgel Rocha CA. MCM3: a novel proliferation marker in oral squamous cell carcinoma. Appl Immunohistochem Mol Morphol. 2018;26(2):120–5.

36. Gao Z, Man X, Li Z, Bi J, Liu X, Li Z, Li J, Zhang Z, Kong C. PLK1 promotes proliferation and suppresses apoptosis of renal cell carcinoma cells by phosphorylating MCM3. Cancer Gene Ther. 2020;27(6):412–23.

37. Zhao Y, Wang Y, Zhu F, Zhang J, Ma X, Zhang D. Gene expression profiling revealed MCM3 to be a better marker than Ki67 in prognosis of invasive ductal breast carcinoma patients. Clin Exp Med. 2020;249:1–11.

38. Han X, Mayca Pozo F, Wisotsky JN, Wang B, Jacobberger JW, Zhang Y. Phosphorylation of minichromosome maintenance 3 (MCM3) by checkpoint kinase 1 (Chk1) negatively regulates DNA replication and checkpoint activation. J Biol Chem. 2015;290(19):12370–8.

39. Sheng X, Dai H, Du Y, Peng J, Sha R, Yang F, Zhou L, Lin Y, Xu S, Wu Y. LncRNA CARMN overexpression promotes prognosis and chemosensitivity of triple negative breast cancer via acting as miR143-3p host gene and inhibiting DNA replication. J Exp Clin Cancer Res. 2021;40(1):1–17.

40. Lee BK, Binge AA, Iyer VR. Wide-ranging functions of E2F4 in transcriptional activation and repression revealed by genome-wide analysis. Nucleic Acids Res. 2011;39(9):3558–73.

41. Mark KMK, Varn FS, Ung MH, Qian F, Cheng C. The E2F4 prognostic signature predicts pathological response to neoadjuvant chemotherapy in breast cancer patients. BMC Cancer. 2017;17(1):017–3297.

42. Conboy CM, Spyrou C, Thorne NF, Wade EJ, Barbosa-Morais NL, Wilson MD, Bhattacharjee A, Young RA, Tavaré S, Lees JA. Cell cycle genes are the evolutionarily conserved targets of the E2F4 transcription factor. PLoS ONE. 2007;2(10):e1061.

43. Garneau H, Paquin MC, Carrier JC, Rivard N. E2F4 expression is required for cell cycle progression of normal intestinal crypt cells and colorectal cancer cells. J Cell Physiol. 2009;221(2):330–8.

44. Ajmal M, Khan MI, Neveling K, Khan YM, Azam M, Waheed NK, Hamel CP, Ben-Yosef T, Baere ED, Koenekoop RK. A missense mutation in the splicing factor gene DHX38 is associated with early-onset retinitis pigmentosa with macular coloboma. J Med Genet. 2014;51(7):444–8.

45. Latif Z, Chakchouk I, Schrauwen I, Lee K, Santos-Cortez RL, Abbe I, Acharya A, Jarral A, Ali I, Lullah E, et al. Confirmation of the role of DHX38 in the etiology of early-onset retinitis pigmentosa. Invest Ophthalmol Vis Sci. 2018;59(11):4552–7.

46. Fraile JM, Manchado E, Lujambio A, Quesada V, Campos-Iglesias D, Webb TR, Lowe SW, López-Otín C, Freije JMP. USP39 deubiquitinase is essential for KRAS oncogene-driven cancer. J Biol Chem. 2017;292(10):4164–75.

Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.